• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

tau病理患者体内F-AV-1451结合定量的建模策略

Modeling Strategies for Quantification of In Vivo F-AV-1451 Binding in Patients with Tau Pathology.

作者信息

Hahn Andreas, Schain Martin, Erlandsson Maria, Sjölin Petter, James Gregory M, Strandberg Olof T, Hägerström Douglas, Lanzenberger Rupert, Jögi Jonas, Olsson Tomas G, Smith Ruben, Hansson Oskar

机构信息

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden.

出版信息

J Nucl Med. 2017 Apr;58(4):623-631. doi: 10.2967/jnumed.116.174508. Epub 2016 Oct 20.

DOI:10.2967/jnumed.116.174508
PMID:27765859
Abstract

Aggregation of hyperphosphorylated tau is a major hallmark of many neurodegenerative diseases, including Alzheimer disease (AD). In vivo imaging with PET may offer important insights into pathophysiologic mechanisms, diagnosis, and disease progression. We describe different strategies for quantification of F-AV-1451 (T807) tau binding, including models with blood sampling and noninvasive alternatives. Fifteen subjects (4 controls, 6 AD, 3 progressive supranuclear palsy, 2 cortico basal syndrome) underwent 180-min PET with F-AV-1451 and arterial blood sampling. Modeling with arterial input functions included 1-, 2-, and 3-tissue-compartment models and the Logan plot. Using the cerebellum as reference region, we applied the simplified reference tissue model 2 and Logan reference plot. Finally, simplified outcome measures were calculated as ratio, with reference to cerebellar concentrations (SUV ratio [SUVR]) and SUVs. Tissue compartment models were not able to describe the kinetics of F-AV-1451, with poor fits in 33%-53% of cortical regions and 80% in subcortical areas. In contrast, the Logan plot showed excellent fits and parameter variance (total volume of distribution SE < 5%). Compared with the 180-min arterial-based Logan model, strong agreement was obtained for the Logan reference plot also for a reduced scan time of 100 min ( = 0.91) and SUVR 100-120 min ( = 0.94), with 80-100 min already representing a reasonable compromise between duration and accuracy ( = 0.93). Time-activity curves and kinetic parameters were equal for cortical regions and the cerebellum in control subjects but different in the putamen. Cerebellar total volumes of distribution were higher in controls than patients. For these methods, increased cortical binding was observed for AD patients and to some extent for cortico basal syndrome, but not progressive supranuclear palsy. The Logan plot provided the best estimate of tau binding using arterial input functions. Assuming that the cerebellum is a valid reference region, simplified methods seem to provide robust alternatives for quantification, such as the Logan reference plot with 100-min scan time. Furthermore, SUVRs between target and cerebellar activities obtained from an 80- to 100-min static scan offer promising potential for clinical routine application.

摘要

过度磷酸化tau蛋白的聚集是包括阿尔茨海默病(AD)在内的许多神经退行性疾病的主要标志。正电子发射断层扫描(PET)的体内成像可能为病理生理机制、诊断和疾病进展提供重要见解。我们描述了定量F-AV-1451(T807)tau蛋白结合的不同策略,包括有血样采集的模型和非侵入性替代方法。15名受试者(4名对照者、6名AD患者、3名进行性核上性麻痹患者、2名皮质基底节综合征患者)接受了180分钟的F-AV-1451 PET检查及动脉血样采集。使用动脉输入函数进行建模包括单组织室模型、双组织室模型和三组织室模型以及洛根图。以小脑作为参考区域,我们应用了简化参考组织模型2和洛根参考图。最后,计算简化的结果测量值作为比值,参照小脑浓度(标准化摄取值比值[SUVR])和标准化摄取值。组织室模型无法描述F-AV-1451的动力学,在33%-53%的皮质区域拟合不佳,在皮质下区域拟合不佳率达80%。相比之下,洛根图显示拟合良好且参数方差较小(分布总体积标准误<5%)。与基于180分钟动脉血样的洛根模型相比,对于扫描时间缩短至100分钟的洛根参考图也获得了高度一致性(r = 0.91),以及100 - 120分钟时的SUVR(r = 0.94),80 - 100分钟已经代表了在时长和准确性之间的合理折衷(r = 0.93)。在对照受试者中,皮质区域和小脑的时间-活性曲线及动力学参数相同,但在壳核中不同。对照者的小脑分布总体积高于患者。对于这些方法,在AD患者中观察到皮质结合增加,在某种程度上皮质基底节综合征患者也有增加,但进行性核上性麻痹患者没有。洛根图使用动脉输入函数提供了对tau蛋白结合的最佳估计。假设小脑是一个有效的参考区域,简化方法似乎为定量提供了可靠的替代方法,例如扫描时间为100分钟的洛根参考图。此外,从80至100分钟静态扫描获得的目标与小脑活性之间的SUVR在临床常规应用中具有良好的潜力。

相似文献

1
Modeling Strategies for Quantification of In Vivo F-AV-1451 Binding in Patients with Tau Pathology.tau病理患者体内F-AV-1451结合定量的建模策略
J Nucl Med. 2017 Apr;58(4):623-631. doi: 10.2967/jnumed.116.174508. Epub 2016 Oct 20.
2
Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.(S)-¹⁸F-THK5117 作为评估 Tau 病理学的 PET 示踪剂的示踪动力学分析。
J Nucl Med. 2016 Apr;57(4):574-81. doi: 10.2967/jnumed.115.158519. Epub 2016 Jan 21.
3
Pharmacokinetic Evaluation of the Tau PET Radiotracer F-T807 (F-AV-1451) in Human Subjects.Tau正电子发射断层显像剂F-T807(F-AV-1451)在人体受试者中的药代动力学评估
J Nucl Med. 2017 Mar;58(3):484-491. doi: 10.2967/jnumed.115.170910. Epub 2016 Sep 22.
4
Kinetic Modeling of the Tau PET Tracer F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects.在健康志愿者和阿尔茨海默病患者中tau PET 示踪剂 F-AV-1451 的动力学建模。
J Nucl Med. 2017 Jul;58(7):1124-1131. doi: 10.2967/jnumed.116.182881. Epub 2016 Dec 1.
5
Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.基于参考组织的18F-AV-1451用于tau成像的动力学评估
J Nucl Med. 2017 Feb;58(2):332-338. doi: 10.2967/jnumed.116.175273. Epub 2016 Sep 1.
6
Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease.Tau正电子发射断层显像剂18F-AV-1451(T807)在认知功能正常、轻度认知障碍和阿尔茨海默病患者中的动力学研究
J Nucl Med. 2016 Oct;57(10):1535-1542. doi: 10.2967/jnumed.115.170027. Epub 2016 May 5.
7
Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [F]MK6240 in human subjects.使用放射性示踪剂[F]MK6240对人体受试者体内tau进行定量的药代动力学建模策略评估。
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2099-2111. doi: 10.1007/s00259-019-04419-z. Epub 2019 Jul 22.
8
In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls.在体鉴定和定量研究人类神经纤维缠结 Tau PET 放射性配体 F-MK-6240 从阿尔茨海默病痴呆到年轻对照的变化。
J Nucl Med. 2019 Jan;60(1):93-99. doi: 10.2967/jnumed.118.209650. Epub 2018 May 18.
9
Spatially constrained kinetic modeling with dual reference tissues improves F-flortaucipir PET in studies of Alzheimer disease.在阿尔茨海默病研究中,采用双参考组织的空间约束动力学建模可改善F-氟代脱氧吡咯葡糖正电子发射断层显像(F-flortaucipir PET)。
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3172-3186. doi: 10.1007/s00259-020-05134-w. Epub 2021 Feb 18.
10
Assessment of [F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function.通过无创自动图像衍生输入函数评估 [F]PI-2620 Tau-PET 定量。
Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3252-3266. doi: 10.1007/s00259-024-06741-7. Epub 2024 May 8.

引用本文的文献

1
Non-invasive arterial input function estimation using an MRA atlas and machine learning.使用MRA图谱和机器学习进行无创动脉输入函数估计
EJNMMI Res. 2025 May 23;15(1):58. doi: 10.1186/s13550-025-01253-3.
2
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.关键血浆磷酸化tau 217生物标志物检测的全面直接比较。
Brain. 2025 Feb 3;148(2):416-431. doi: 10.1093/brain/awae346.
3
A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests.关键血浆磷酸化tau 217生物标志物检测的全面直接比较
medRxiv. 2024 Jul 5:2024.07.02.24309629. doi: 10.1101/2024.07.02.24309629.
4
Albumin Nanoparticle-Based Drug Delivery Systems.白蛋白纳米粒药物传递系统。
Int J Nanomedicine. 2024 Jul 10;19:6945-6980. doi: 10.2147/IJN.S467876. eCollection 2024.
5
Tau PET imaging in progressive supranuclear palsy: a systematic review and meta-analysis.tau PET 成像在进行性核上性麻痹中的应用:系统评价和荟萃分析。
J Neurol. 2023 May;270(5):2451-2467. doi: 10.1007/s00415-022-11556-3. Epub 2023 Jan 12.
6
The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification.RSNA QIBA 淀粉样蛋白 PET 成像生物标志物分析用于脑淀粉样蛋白定量。
J Nucl Med. 2023 Feb;64(2):294-303. doi: 10.2967/jnumed.122.264031. Epub 2022 Sep 22.
7
Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [F]-AV-1451 PET data.常见参考区域对横断面和纵向[F]-AV-1451 PET 数据中区域 tau 模式的影响。
Neuroimage. 2021 Nov;243:118553. doi: 10.1016/j.neuroimage.2021.118553. Epub 2021 Sep 3.
8
Spatially constrained kinetic modeling with dual reference tissues improves F-flortaucipir PET in studies of Alzheimer disease.在阿尔茨海默病研究中,采用双参考组织的空间约束动力学建模可改善F-氟代脱氧吡咯葡糖正电子发射断层显像(F-flortaucipir PET)。
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3172-3186. doi: 10.1007/s00259-020-05134-w. Epub 2021 Feb 18.
9
Clinical validity of increased cortical uptake of [F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework.在结构化的 5 阶段生物标志物开发框架中,[F]flortaucipir 摄取增加作为阿尔茨海默病生物标志物的皮质 PET 的临床有效性。
Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2097-2109. doi: 10.1007/s00259-020-05118-w. Epub 2021 Feb 6.
10
The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.在女性和淀粉样蛋白阳性的年轻受试者中,tau 聚集物的积累速度更高。
Brain. 2020 Dec 1;143(12):3805-3815. doi: 10.1093/brain/awaa327.